ESMO World Congress on Gastrointestinal Cancer 2016

Oncology Meeting Resources

29 Jun - 02 Jul 2016, Barcelona, Spain

World GI 2016 Square Image

The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts from the ESMO World GI 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.





Format available

http://oncologypro.esmo.org/Meeting-Resourc...-to-breast-cancer-patients-and-healthy-women

Many studies report that frailty, cachexia and decreased physical function during chemotherapy (CT) of cancer patients predict a higher mortality risk. Although a high prevalence of these symptoms in...

Date: 29 Jun 2016
Presenter: K. Stuecher
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-the-therapeutic-effect-in-colorectal-cancer

We previously reported that the administration of BEZ235, a dual PI3K/mTOR inhibitor, before radiotherapy (RT) enhances the radiotherapeutic effect in colorectal cancer cells both in vitro and in vivo....

Date: 29 Jun 2016
Presenter: F. Wei Ming
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ic-gastric-patients-after-curative-resection

F-18 Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has been known to be an effective imaging modality in detecting gastric cancer recurrence.

Date: 29 Jun 2016
Presenter: J.W. Lee
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...section-compared-with-conventional-endoscopy

Endoscopic submucosal dissection(ESD) is currently the standard practice for a subgroup of patients with early gastric cancer (EGC) in Korea and Japan. For the therapeutic decision of ESD or laparoscopic...

Date: 29 Jun 2016
Presenter: J.S. Lee
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...nd-mortality-in-patients-with-gastric-cancer

Surgical resection for gastric adenocarcinoma is associated with significant post-operative morbidity and mortality. Recent studies have demonstrated the correlation between sarcopenia and adverse...

Date: 29 Jun 2016
Presenter: S. O'Brien
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...imary-HCC-in-CT-after-locoregional-treatment

Locoregional treatment includes transarterial embolization by lipiodol chemotherapy mixture or drug eluting beads. Also, it includes percutaneous local thermal ablation by radiofrequency, microwave,...

Date: 29 Jun 2016
Presenter: A. Bessar
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...erapy-for-Locally-Recurrent-Bile-Duct-Cancer

We investigated the clinical outcome and prognostic factors of chemoradiotherapy (CRT) for locally recurrent bile duct cancer after curative surgical resection.

Date: 29 Jun 2016
Presenter: J.I. Yu
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...erapy-and-proton-beam-therapy-in-anal-cancer

Volumetric modulated arc therapy (VMAT) enables dynamic modulation of angular dose rate through changes in gantry speed, linear accelerator dose rate, and multileaf collimator motion.

Date: 29 Jun 2016
Presenter: J. Hansen
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...-boost-combined-with-concurrent-chemotherapy

Squamous cell anal canal carcinoma is a rather rare malignancy, no more than 4% of all gastrointestinal tumors although is incident is increasing. Definitive chemoradiation is the standard management for anal squamous cell carcinoma.

Date: 29 Jun 2016
Presenter: L. Diaz Gomez
Resources: Abstract

http://oncologypro.esmo.org/Meeting-Resourc...ence-at-The-National-Cancer-Institute-Mexico

Gallbladder cancer (GBC) is a rare biliary malignancy of extremely aggressive nature, and its prognosis is very dismal. Its presentation in our country is most of the time with advanced disease.

Date: 29 Jun 2016
Presenter: J. Zamora Moreno
Resources: Abstract